Table 1. Patient and treatment details.
| TOTAL | |
|---|---|
| Number of Patients | 162 |
| Sex M |
83 (51%) |
| Age at Diagnosis Median (quartiles) |
55 (46,66) |
| IPI Score 0-1 2 3 4-5 |
75 (46%) 37 (23%) 33 (20%) 17 (11%) |
| GCB/non-GCB/unknown (% non-GCB where known) |
56/76/30 (47%) |
| Mean 2y Outcomes (days)[range] (95% CI) |
OS: 538 [480–596] EFS: 423 [366–481] |
| R-CHOP CHOP |
134 (83 %) 28 (17 %) |
| Chemotherapy Cycles: <6 6 >6 |
19 (12 %) 84 (52 %) 59 (36 %) |
| Consolidation Radiotherapy Total (Bulky disease) (Non-bulky site) |
42 (28 %) (38) (4) |
| Number of patients with significant Rx delays or dose reductions |
23/100 (23 %) (48 not known) |
rituximab, cyclophosphamide, doxorubicin (Hydroxydaunomycin), vincristine (oncovin ®), prednisolone (a steroid) (R-CHOP).